Summary
- Bristol-Myers agreed to pay a 54% premium to acquire Celgene.
- Celgene shareholders get an immediate price boost plus the long-term potential to participate in cheap BMY stock.
- The deal provides a 40% EPS boost for Bristol-Myers and cost synergies of $2.5 billion.
- Free cash flows should allow for the elimination of debt by peak Revlimid sales in 2022.
- The conservative EPS target is $7 by 2020.
Rarely are mega mergers so appealing as the Bristol-Myers Squibb (BMY) bid to buy Celgene (CELG). The latter biopharma had been beaten to such a pulp that the deal provides an immediate upside for suffering shareholders and the potential to participate in substantial earnings upside for the combined entity. The merger appears a win-win for both sides.
Image Source: Bristol-Myers/Celgene merger presentation
Merger Details
On January 3, Bristol-Myers announced the intent to pay $74 billion to purchase Celgene. The deal values Celgene at $102.43 a share plus a potential $9 CVR (contingent value right).
As detailed below, Celgene shareholders will get $50 in cash and one share of Bristol-Myers plus the CVR. The deal is expected to close by Q3.

